Literature DB >> 9062973

Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis.

R Rajalingam1, D P Singal, N K Mehra.   

Abstract

We have studied TAP polymorphism in a panel of 40 healthy individuals, 57 patients with pulmonary tuberculosis (PTB) and 50 with tuberculoid (TT) leprosy from North India. Only TAP2-A/F occurred with a significantly increased frequency in PTB patients as compared to controls (82.5% vs. 52.5%, P < 0.002, Pc < 0.01) giving a high relative risk of 4.3. On the other hand, TAP2-B was significantly increased in TT leprosy as compared to controls (76% vs. 47.5%, Pc < 0.003, RR 3.5) particularly in patients positive for HLA-DR15 than controls carrying DR15 (77.5% vs. 50%, P < 0.03, RR = 3.4). Further, TAP2-B allele was positively associated with DR15 negative PTB patients as compared to the DR15 positive group (43.8% vs. 17.1%, P < 0.04, RR = 0.3). This study along with our earlier studies on HLA association in mycobacterial diseases suggests that in addition to HLA-DR15 alleles in the TAP2 region influence susceptibility to PTB and TT leprosy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062973     DOI: 10.1111/j.1399-0039.1997.tb02731.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  11 in total

1.  Association of variants in BAT1-LTA-TNF-BTNL2 genes within 6p21.3 region show graded risk to leprosy in unrelated cohorts of Indian population.

Authors:  Shafat Ali; Rupali Chopra; Shweta Aggarwal; Amit Kumar Srivastava; Ponnusamy Kalaiarasan; Dheeraj Malhotra; Sailesh Gochhait; Vijay K Garg; S N Bhattacharya; Rameshwar N K Bamezai
Journal:  Hum Genet       Date:  2011-11-10       Impact factor: 4.132

Review 2.  Leprosy in the 21st century.

Authors:  Cassandra White; Carlos Franco-Paredes
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

3.  A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression.

Authors:  Bridgett Knox; Yong Wang; Lora J Rogers; Jiekun Xuan; Dianke Yu; Huaijin Guan; Jiwei Chen; Tieliu Shi; Baitang Ning; Susan A Kadlubar
Journal:  Environ Mol Mutagen       Date:  2017-12-05       Impact factor: 3.216

Review 4.  Leprosy and the human genome.

Authors:  Elizabeth A Misch; William R Berrington; James C Vary; Thomas R Hawn
Journal:  Microbiol Mol Biol Rev       Date:  2010-12       Impact factor: 11.056

Review 5.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

6.  Effect of multiple genetic polymorphisms on antigen presentation and susceptibility to Mycobacterium tuberculosis infection.

Authors:  Stewart T Chang; Jennifer J Linderman; Denise E Kirschner
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

7.  Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy.

Authors:  Pierre-Yves Bochud; Thomas R Hawn; M Ruby Siddiqui; Paul Saunderson; Sven Britton; Isaac Abraham; Azeb Tadesse Argaw; Marta Janer; Lue Ping Zhao; Gilla Kaplan; Alan Aderem
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

8.  Characterization and allelic variation of the transporters associated with antigen processing (TAP) genes in the domestic dog (Canis lupus familiaris).

Authors:  Gregory S Gojanovich; Peter Ross; Savannah G Holmer; Jennifer C Holmes; Paul R Hess
Journal:  Dev Comp Immunol       Date:  2013-07-25       Impact factor: 3.636

Review 9.  Human genetics of common mycobacterial infections.

Authors:  Natascha Remus; Alexandre Alcaïs; Laurent Abel
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Association of LMP/TAP gene polymorphisms with tuberculosis susceptibility in Li population in China.

Authors:  Danmei Wang; Yue Zhou; Limin Ji; Tong He; Feng Lin; Rong Lin; Tangchang Lin; Yanna Mo
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.